文献速递前列腺癌

单核苷酸多态性与前列腺特异性抗原联合预测前列腺癌风险

Risk Prediction of Prostate Cancer with Single Nucleotide Polymorphisms and Prostate Specific Antigen.
PubMed 文献 · J Urol · 2019-01-01

基于芬兰人群筛查试验和DNA研究,纳入20,575名接受PSA检测的男性及部分多基因风险评分样本,构建贝叶斯预测模型,发现7个SNP联合PSA的ROC AUC达88.8%,显著高于单用PSA的70.1%,联合信息可提高风险分层并允许更高PSA cutoff。

要点

  • 7个SNP联合PSA的AUC为88.8%,显著优于单用PSA的70.1%。
  • 联合后验比值随PSA升高而增加,4 ng/ml时为3.7,10 ng/ml时为98.2。
  • 联合信息有助于风险分层,优化前列腺癌筛查性能。

核心结论

  • 多个遗传变异联合PSA信息比单用PSA能更好地预测前列腺癌风险,并允许采用更高的PSA cutoff。
  • 联合信息为风险分层提供了基础,可用于优化前列腺癌筛查性能。

研究设计与样本

  • 前瞻性研究,纳入芬兰人群前列腺癌筛查试验中20,575名接受PSA检测的男性,其中4,967名有基于66个SNP的多基因风险评分。
  • 另纳入芬兰前列腺癌DNA研究的5,269个样本,基于7个SNP。
  • 构建贝叶斯预测模型,序贯结合遗传信息与PSA,比较单用PSA,分析限于PSA≥4 ng/ml的受试者。

主要发现

  • 基于7个SNP联合PSA的后验比值:PSA 4 ng/ml时为3.7,6 ng/ml时为14.2,8 ng/ml时为40.7,10 ng/ml时为98.2。
  • 7个SNP风险评分联合PSA的ROC AUC为88.8%(95% CI 88.6-89.1),单用PSA为70.1%(95% CI 69.6-70.7)。
  • 结合所有前列腺癌易感多基因时,AUC进一步升至96.7%(95% CI 96.5-96.9)。

关键数值与推荐

  • 7个SNP联合PSA的ROC AUC为88.8%(95% CI 88.6-89.1),单用PSA为70.1%(95% CI 69.6-70.7)。
  • 全部易感多基因联合时ROC AUC为96.7%(95% CI 96.5-96.9)。
  • 后验比值在PSA 4、6、8、10 ng/ml时分别为3.7、14.2、40.7、98.2。

临床怎么用

  • 可将SNP信息与PSA联合用于前列腺癌风险分层,提高筛查特异性。
  • 联合模型允许采用更高的PSA cutoff,可能减少不必要的活检。

局限性

  • 研究基于芬兰人群,外推至其他人群需谨慎。
  • 分析限于PSA≥4 ng/ml的受试者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Combined information on single nucleotide polymorphisms and prostate specific antigen offers opportunities to improve the performance of screening by risk stratification. We aimed to predict the risk of prostate cancer based on prostate specific antigen together with single nucleotide polymorphism information. MATERIALS AND METHODS: We performed a prospective study of 20,575 men with prostate specific antigen testing and 4,967 with a polygenic risk score for prostate cancer based on 66 single nucleotide polymorphisms from the Finnish population based screening trial of prostate cancer and 5,269 samples of 7 single nucleotide polymorphisms from the Finnish prostate cancer DNA study. A Bayesian predictive model was built to estimate the risk of prostate cancer by sequentially combining genetic information with prostate specific antigen compared with prostate specific antigen alone in study subjects limited to those with prostate specific antigen 4 ng/ml or above. RESULTS: The posterior odds of prostate cancer based on 7 single nucleotide polymorphisms together with the prostate specific antigen level ranged from 3.7 at 4 ng/ml, 14.2 at 6 and 40.7 at 8 to 98.2 at 10 ng/ml. The ROC AUC was elevated to 88.8% (95% CI 88.6-89.1) for prostate specific antigen combined with the risk score based on 7 single nucleotide polymorphisms compared with 70.1% (95% CI 69.6-70.7) for prostate specific antigen alone. It was further escalated to 96.7% (95% CI 96.5-96.9) when all prostate cancer susceptibility polygenes were combined. CONCLUSIONS: Expedient use of multiple genetic variants together with information on prostate specific antigen levels better predicts the risk of prostate cancer than prostate specific antigen alone and allows for higher prostate specific antigen cutoffs. Combined information also provides a basis for risk stratification which can be used to optimize the performance of prostate cancer screening.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Li-Sheng Chen S, Ching-Yuan Fann J, Sipeky C, et al. Risk Prediction of Prostate Cancer with Single Nucleotide Polymorphisms and Prostate Specific Antigen. J Urol. 2019. PMID: 30366021. doi:10.1016/j.juro.2018.10.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。